MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Zileuton
CAS No. : 111406-87-2
MCE 国际站：Zileuton
产品活性：Zileuton是有效，选择性的5-脂氧合酶抑制剂，具有抗哮喘特性。
研究领域：Metabolic Enzyme/Protease | Apoptosis
作用靶点：Lipoxygenase | Ferroptosis
In Vitro: In anti-CD3-treated cells, IL-2 decreases in zileuton-treated and untreated cells with increasing incubation time. Zileuton likely reduces IL-2 levels by inhibiting 5-lipoxygenase, hence leukotriene B4 production, an IL-2 inducer.
In Vivo: In zileuton (5 mg/kg, p.o.) treated I/R rat, the effect of zileuton to decrease NF-κB expression does not change significantly in the presence of COX inhibitors, and the group reveals significantly lower level of NF-κB staining. Zileuton (5 mg/kg, p.o.) treatment given to I/R rats decreases apoptotic index significantly. Zileuton has no significant effect on increased serum TNF-α levels in I/R group. Zileuton (1,200 mg/kg) inhibits the polyp formation in APCΔ468 colon and small intestine. Zileuton treatment inhibits the proliferation rates of non epithelial cells in polyps, and increases the apoptosis rates in polyps in rat. There is significant increase in the number of apoptotic cells in the Zileuton-treated cells both in small intestine and in the colon. The reduced proliferation rate may significantly contribute to the reduction of polyposis in both the small intestine and colon of Zileuton-fed APCΔ468 mice.
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Apoptosis Compound Library | Immunology/Inflammation Compound Library | Metabolism/Protease Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Drug Repurposing Compound Library | Ferroptosis Compound Library | Anti-COVID-19 Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Lipid Metabolism Compound Library | Tumorigenesis-Related Compound Library | Rare Diseases Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Non-steroidal Anti-Inflammatory Compound Library | Heterocyclic Compound Library | Withdrawn Drug Compound Library | Off-patent Drug Library | Metabolic Enzyme Compound Library | Highly Selective Inhibitors Library | Cell Death Library | Bioactive Compound Library Max | Anti-Fibrosis Compound Library | Ferrostatin-1 | Erastin | Cisplatin | Cycloheximide | RSL3 | Acetylcysteine | Sorafenib | ML385 | Necrostatin-1 | SP600125 | Rosiglitazone | Liproxstatin-1 | Curcumin | Simvastatin | Acetaminophen | Hemin | L-Glutathione reduced | Trolox | Roxadustat | NADPH tetrasodium salt | Lapatinib | TBHQ | Lovastatin | Sulfasalazine | Pifithrin-α hydrobromide | U-73122 | Pioglitazone | iFSP1 | BODIPY 581/591 C11 | Atorvastatin hemicalcium salt
热门产品线：重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。
